Skip to main content
SpringerLink
Log in

Cardiovascular Pharmacogenetics

  • Book
  • © 2004

Overview

Editors:
  1. Martin R. Wilkins

    1. Experimental Medicine & Toxicology Imperial College London, Hammersmith Campus, London, UK

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

Part of the book series: Handbook of Experimental Pharmacology (HEP, volume 160)

This is a preview of subscription content, log in via an institution to check access.

Access this book

Log in via an institution
eBook USD 259.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 329.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book USD 329.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (15 chapters)

  1. Front Matter

    Pages I-X
    Download chapter PDF

  2. The Role of Genotyping in Pharmacological Therapy

    • K. Lindpaintner
    Pages 1-23

  3. Pharmacogenetics and the Treatment of Cardiovascular Disease

    • S. K. Tate, D. B. Goldstein
    Pages 25-37

  4. Genetic Polymorphisms and Cardiovascular Drug Metabolism

    • A. R. Boobis, T. Shiga, R. J. Edwards
    Pages 39-77

  5. Genes That Modify Susceptibility to Atherosclerosis: Targets for Drug Action

    • J. W. Knowles
    Pages 79-105

  6. Lipid-Lowering Responses Modified by Genetic Variation

    • B. R. Winkelmann, M. M. Hoffmann, W. März
    Pages 107-147

  7. The Genetic Basis of Essential Hypertension and Its Implications for Treatment

    • K. M. O’Shaughnessy, M. R. Wilkins
    Pages 149-176

  8. Genetic Predisposition to Cardiac Hypertrophy

    • A. J. Marian
    Pages 177-202

  9. Genetic Determinants of Susceptibility, Prognosis and Treatment in Heart Failure

    • T. Stanton, J. M. C. Connell, J. J. V. McMurray
    Pages 203-222

  10. The Genetics of Cardiac Channelopathies: Implications for Therapeutics

    • D. M. Roden
    Pages 223-241

  11. Insulin Resistance and Cardiovascular Disease: New Insights from Genetics

    • A. Vidal-Puig, E. D. Abel
    Pages 243-279

  12. Genetic Disruption of Nitric Oxide Synthases and Cardiovascular Disease: Lessons from a Candidate Gene

    • P. L. Huang
    Pages 281-310

  13. Association of Thrombotic Disease with Genetic Polymorphism of Haemostatic Genes: Relevance to Pharmacogenetics

    • E. G. D. Tuddenham
    Pages 311-322

  14. The Influence of Genetic Factors on Leukocyte and Endothelial Cell Adhesion Molecules

    • R. M. Rao, A. I. Russell, T. Vyse, D. O. Haskard
    Pages 323-339

  15. Genetic Regulation of Metalloproteinase Activity: Pathogenic and Therapeutic Implications

    • A. M. Henney
    Pages 341-358

  16. Current Perspectives on Gene and Cell-Based Therapies for Myocardial Protection, Rescue and Repair

    • L. G. Melo, A. S. Pachori, D. Kong, V. J. Dzau
    Pages 359-404

  17. Back Matter

    Pages 405-407
    Download chapter PDF
Back to top

Keywords

About this book

The Human Genome Project was sold to the general public largely on the basis that a complete picture of the structure of human DNA would lead to new and better medicines. These medicines would be better because they would be tailored to individual patients, maximising the chances of a therapeutic response and mi­ nimising the risks of an adverse event. Taking the idea further, pundits have pre­ dicted that the time will come when we could carry our DNA on a card which could be read rapidly and enable the physician to choose the best drug. This is the future. This is pharmacogenetics. When the draft human DNA sequence was announced and scientists were as­ ked how this would help drug development, the example most frequently given was the debrisoquine model - where poor metabolisers of this hypotensive agent are exposed to higher plasma levels from a standard dose and at risk of collapse from excessive hypotension. This observation was made over 20 years ago and predated designs to sequence the human genome. Nonetheless, it raised aware­ ness of variation in drug metabolism and was correctly assigned to genetic poly­ morphisms affecting CYP2D6. Together with the discovery of pseudocholinestera­ se deficiency, it marked the birth of pharmacogenetics. The debrisoquine example is an interesting one and worthy of further analysis.

Editors and Affiliations

  • Experimental Medicine & Toxicology Imperial College London, Hammersmith Campus, London, UK

    Martin R. Wilkins

Bibliographic Information

  • Book Title: Cardiovascular Pharmacogenetics

  • Editors: Martin R. Wilkins

  • Series Title: Handbook of Experimental Pharmacology

  • DOI: https://doi.org/10.1007/978-3-662-06214-2

  • Publisher: Springer Berlin, Heidelberg

  • eBook Packages: Springer Book Archive

  • Copyright Information: Springer-Verlag Berlin Heidelberg 2004

  • Hardcover ISBN: 978-3-540-40204-6Published: 02 December 2003

  • Softcover ISBN: 978-3-642-07291-8Published: 23 January 2011

  • eBook ISBN: 978-3-662-06214-2Published: 17 April 2013

  • Series ISSN: 0171-2004

  • Series E-ISSN: 1865-0325

  • Edition Number: 1

  • Number of Pages: X, 407

  • Topics: Cardiology, Pharmacology/Toxicology, Neurosciences, Neurology, Human Genetics

Publish with us

Policies and ethics

Back to top

Search

Navigation